Safety and vaccine efficacy of a glycoprotein G deficient strain of infectious laryngotracheitis virus delivered in ovo.
Infectious laryngotracheitis virus (ILTV), an alphaherpesvirus, causes respiratory disease in chickens and is commonly controlled by vaccination with conventionally attenuated vaccines. Glycoprotein G (gG) is a virulence factor in ILTV and a gG deficient strain of ILTV (ΔgG-ILTV) has shown potential for use as a vaccine. In the poultry industry vaccination via drinking water is common, but technology is now available to allow quicker and more accurate in ovo vaccination of embryos at 18 days of incubation. In this study ΔgG-ILTV was delivered to chicken embryos at three different doses (10(2), 10(3) and 10(4) plaque forming units per egg) using manual in ovo vaccination. At 20 days after hatching, birds were challenged intra-tracheally with wild type ILTV and protection was measured. In ovo vaccination was shown to be safe, as there were no developmental differences between birds from hatching up to 20 days of age, as measured by weight gain. The highest dose of vaccine was the most efficacious, resulting in a weight gain not significantly different from unvaccinated/unchallenged birds seven days after challenge. In contrast, birds vaccinated with the lowest dose showed weight gains not significantly different from unvaccinated/challenged birds. Gross pathology and histopathology of the trachea reflected these observations, with birds vaccinated with the highest dose having less severe lesions. However, qPCR results suggested the vaccine did not prevent the challenge virus replicating in the trachea. This study is the first to assess in ovo delivery of a live attenuated ILTV vaccine and shows that in ovo vaccination with ΔgG-ILTV can be both safe and efficacious.
Asia-Pacific Centre for Animal Health, The University of Melbourne, Victoria, 3010, Australia. legionea@unimelb.edu.au
Alistair R
AR
Legione
Mauricio J C
MJ
Coppo
Sang-Won
SW
Lee
Amir H
AH
Noormohammadi
Carol A
CA
Hartley
Glenn F
GF
Browning
James R
JR
Gilkerson
Denise
D
O'Rourke
Joanne M
JM
Devlin
D000818:Animals; D002645:Chickens; D017353:Gene Deletion; D006023:Glycoproteins / Q000235:genetics; D006566:Herpesviridae Infections / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D001352:Herpesvirus 1, Gallid / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D010063:Ovum / Q000821:virology*; D011201:Poultry Diseases / Q000473:pathology / Q000517:prevention & control* / Q000821:virology*; D014132:Trachea / Q000473:pathology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D037521:Virulence Factors / Q000235:genetics
D006023:Glycoproteins; D014613:Vaccines, Attenuated; D014764:Viral Proteins; D014765:Viral Vaccines; D037521:Virulence Factors